A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema

Inclusion Criteria: * A female subject is eligible to participate if she is of: Non-childbearing potential or child-bearing potential and agrees to contraception for an appropriate period of time * Diagnosis of diabetes mellitus (type 1 or type 2) * Confirmation of DME in the study eye by angiography * Confirmation of retinal thickening in the study eye by study doctor * Best corrected visual acuity score of 78-24 letters in the study eye Exclusion Criteria: * Additional eye disease in the study eye that could compromise study assessments * Intraocular surgery, or laser photocoagulation in the study eye within 3 months of dosing * Uncontrolled intraocular pressure in the study eye despite treatment with glaucoma medication * Uncontrolled diabetes * Certain types of liver disease * Severe reduction in kidney function OR removal of a kidney OR kidney transplant * Blood pressure higher than normal despite lifestyle changes and treatment with medications * Certain medications that may interfere with the study medication or eye assessments (these will be identified by the study doctor) * Current severe heart failure * Severe asthma that is poorly controlled with medication * Previous severe allergic reaction to food, medications, drink, insect stings, etc * If both birth parents are at least 50% Japanese, Chinese, or Korean ancestry, must have a blood sample collected for Lp-PLA2 activity. Those with Lp-PLA2 activity less than or equal to 20.0 nmol/min/mL are excluded * Recent participation in a study of an investigational medication * Any other reason the investigator deems the subject should not participate in the study * Other protocol-defined inclusion/exclusion criteria may apply